SCARB1 and atherosclerosis: Interestingly, in support of the anti-atherogenic properties of hepatocyte SR-B1, liver-specific transgenic or adenoviral overexpression of SR-B1 in hyperlipidemic apo E or LDL receptor knockout mice had demonstrated the reduction in atherosclerosis predisposition [3,56,66].